Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $168.86. The company's market cap stands at 17.1B, with a P/E ratio of 24.41.
During the trading session on 2026-11-09, Neurocrine(NBIX) shares reached a daily high of $169.83 and a low of $162.99. At a current price of $168.86, the stock is +3.6% higher than the low and still -0.6% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.5M, versus its average volume of 1.73M.
The stock's 52-week range extends from a low of $122.14 to a high of $186.12.
The stock's 52-week range extends from a low of $122.14 to a high of $186.12.
NBIX News
Neurocrine Biosciences ((NBIX)) has held its Q3 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences delivered a strongly positiv...
Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy)....
Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report) or Gu...
Analyst ratings
86%
of 29 ratingsMore NBIX News
Neurocrine Biosciences, Inc. ( ) recently posted some strong earnings, and the market responded positively. We did some digging and found some further encouragi...
Neurocrine Biosciences reported third quarter 2026 revenue of US$1,122.7m and net income of US$206.5m, with record net product sales from INGREZZA, CRENESSITY a...
Neurocrine Biosciences (NBIX) has disclosed a new risk, in the Corporate Activity and Growth category. Neurocrine Biosciences faces integration risk following...
Why Neurocrine Biosciences Stock Is Back in Focus Neurocrine Biosciences (NBIX) is drawing fresh attention after third quarter 2026 results showed revenue of U...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.